Dolutegravir (Tivicay®, Triumeq®): New study suggests risk of birth defects in babies born to women who were treated for HIV infection
2018.05.22
Active substance: dolutegravir
The European Medicines Agency (EMA) is currently evaluating preliminary results from a study which found 4 cases of birth defects.
To the risk information full text (available in German only)
For details on the review please click on the following link to the homepage of the European Medicines Agency (EMA):